Key facts
- This page summarizes Christopher Ryan Sullivan's Form 4 filing for Avalo Therapeutics, Inc. (AVTX).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 13 Jun 2023, 16:41.
Christopher Ryan Sullivan - 09 Jun 2023 Form 4 Insider Report for Avalo Therapeutics, Inc. (AVTX)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- AVTX
- Reported as of
- 09 Jun 2023
- Net transaction value
- +$1,748
- SEC form
- 4
- Accepted by SEC
- 13 Jun 2023, 16:41:21 UTC
- Prior SEC filing
- 17 May 2023
- Next SEC filing
- 14 Aug 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jennifer Zoltoski, by Power of Attorney
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Christopher Ryan Sullivan filed Form 4 for Avalo Therapeutics, Inc. (AVTX) on 13 Jun 2023.
Change
- Previous filing in this sequence was filed on 17 May 2023.
- Current net transaction value: +$1,748.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AVTX
transaction
Common Stock
Purchase
- Transaction value
- $1,748
- Shares
- +511
- Change %
- +68%
- Price
- $3.42*
- Shares after
- 1,262
- Date
- 09 Jun 2023
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
These shares were acquired under the Issuer's 2016 Employee Stock Purchase Plan.